Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Singapore General Hospital
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Sarcopenia
Overview
Brief Summary
Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%.
In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups.
The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments.
Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 21 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •body mass index ≥ 27.5kg/m2
- •able to provide informed consent.
Exclusion Criteria
- •unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)
- •pregnant women
- •history of bariatric procedures or surgeries
- •on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)
Outcomes
Primary Outcomes
Sarcopenia
Time Frame: Outcome measures will be recorded at baseline only.
Skeletal muscle mass Skeletal muscle mass measurement will be obtained via bioimpedance analysis using the TANITA MC 780 MA Multi-frequency Segmental Body Composition Analyser. Low skeletal muscle mass will be defined by percentage of skeletal muscle mass divided by body weight of ≤ 37% in males and ≤ 27.6% in females.
Handgrip strength
Time Frame: Outcome measures will be recorded at baseline only.
Handgrip strength will be measured using the Jamar handgrip dynamometer. Two trials will be performed for each hand, and the maximum strength will be used for diagnosis.
5-time chair stand test
Time Frame: Outcome measures will be recorded at baseline only.
Time taken (seconds) to perform 5 sit-to-stand repetitions
30-second sit-to-stand test
Time Frame: Outcome measures will be recorded at baseline only.
Number of sit-to-stand repetitions performed in 30 seconds
Secondary Outcomes
- Aerobic capacity(At baseline)
- Physical activity questionnaire(At baseline)
- Dietary questionnaire(At baseline)